



Media Release

Change in the management of the MiP Pharma Group – Peter Lenbet succeeds Martin Osterhues as CFO

Blieskastel, 26.6.2024. A change is imminent in the management of the MiP Pharma Group based in Blieskastel. Peter Lenbet, currently Head of Controlling, will be the second Managing Director and CFO alongside CEO Dr Friedrich Sernetz as of July 1st, 2024.

The Saarland-based MiP Pharma Group produces and distributes prescription generics, primarily antibiotics, over-the-counter medicines, and medical devices. With over 270 employees based in Blieskastel and a modern sterile production facility in Homburg/Saar, MiP contributes reliably and sustainably to securing the supply of medicines in Germany.

There has been a mutually agreed change in the company's management: Peter Lenbet, currently Head of Controlling, will take over the position of Chief Financial Officer (CFO) of MiP Pharma Holding GmbH at the start of the new financial year on July 1st, 2024. He also joins Dr Friedrich Sernetz, CEO of the MiP Pharma Group, as the Group's second Managing Director. The current CFO Martin Osterhues is expected to remain with MiP Pharma until the end of September 2024 to ensure a smooth transition.

Peter Lenbet has been with MiP Pharma since 2023. Previously, he was Director Finance at Hamm Reno Group GmbH, Commercial Director at OKI Systems (Deutschland) GmbH, and Head of Controlling and Finance at NiGuRa Metzler Optics International GmbH.

Dr Axel Müller, Chairman of the Advisory Board, comments on the change: "Over the past three and a half years, Martin Osterhues has significantly contributed to developing and implementing the growth strategy for the MiP Pharma Group. We want to express our sincere thanks and appreciation to him for these achievements."

Dr Friedrich Sernetz adds: "I look forward to working with Peter Lenbet in the management team. His many years of experience in finance and administration make him a proven expert in his field and, as CFO at MiP, he will provide important impetus for the continued optimization of our business processes."



About MiP Pharma Group

MiP Pharma Group (MiP Pharma) produces and distributes prescription generics, especially antibiotics, over-the-counter medicines, and medical products. Its main markets are Germany and Poland as well as some other Eastern European markets. Sales focus on the hospital business and selected groups of specialists and, in particular, dentists. MiP Pharma operates two production sites in Saarland/Germany. With over 270 employees and around 400 regulatory approvals, MiP Pharma generated total sales of over € 50 m in the last fiscal year. Since November 2020, previously family-run MiP Pharma has been a portfolio company of the Berlin-based financial investor capiton AG.

The expansion of the production facilities and the construction of a new administration building at the Homburg location will be completed shortly. The company is thus strengthening its production capacities in future-oriented technologies such as sterile production as well as its activities as a pharmaceutical contract manufacturer while creating new jobs in the region. The total investment volume totals in the double-digit million range; the investments are also subsidized by funds from the Saarland.

Media Contact

Evelyn Back
+49 176 636 13 964
buero@evelynback.com